- Home
- TMHC vs AXSM Comparison
TMHC vs AXSM Comparison
Compare TMHC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMHC
- AXSM
- Stock Information
- Founded
- TMHC 1936
- AXSM 2012
- Country
- TMHC United States
- AXSM United States
- Employees
- TMHC N/A
- AXSM N/A
- Industry
- TMHC Homebuilding
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- TMHC Consumer Discretionary
- AXSM Health Care
- Exchange
- TMHC Nasdaq
- AXSM Nasdaq
- Market Cap
- TMHC 6.1B
- AXSM 5.1B
- IPO Year
- TMHC 2013
- AXSM 2015
- Fundamental
- Price
- TMHC $63.45
- AXSM $105.44
- Analyst Decision
- TMHC Buy
- AXSM Strong Buy
- Analyst Count
- TMHC 8
- AXSM 17
- Target Price
- TMHC $75.63
- AXSM $171.65
- AVG Volume (30 Days)
- TMHC 1.1M
- AXSM 649.3K
- Earning Date
- TMHC 07-23-2025
- AXSM 08-04-2025
- Dividend Yield
- TMHC N/A
- AXSM N/A
- EPS Growth
- TMHC 23.02
- AXSM N/A
- EPS
- TMHC 8.60
- AXSM N/A
- Revenue
- TMHC $8,364,403,000.00
- AXSM $432,157,000.00
- Revenue This Year
- TMHC N/A
- AXSM $62.84
- Revenue Next Year
- TMHC $0.95
- AXSM $60.02
- P/E Ratio
- TMHC $7.38
- AXSM N/A
- Revenue Growth
- TMHC 12.19
- AXSM 72.16
- 52 Week Low
- TMHC $51.90
- AXSM $72.21
- 52 Week High
- TMHC $75.49
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- TMHC 62.20
- AXSM 47.99
- Support Level
- TMHC $59.60
- AXSM $102.26
- Resistance Level
- TMHC $65.90
- AXSM $106.35
- Average True Range (ATR)
- TMHC 1.95
- AXSM 3.09
- MACD
- TMHC 0.55
- AXSM 0.15
- Stochastic Oscillator
- TMHC 73.43
- AXSM 66.44
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.